Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NCT01985555
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
85
Enrollment
INDUSTRY
Sponsor class
Conditions
Tumors
Interventions
DRUG:
Volitinib(HMPL-504)
Sponsor
Hutchison Medipharma Limited